Natarajan Kiruthiga, Thangavelu Prabha, Chellappa Selvinthanuja, Kulandaivel Srinivasan, Thangavel Sivakumar


The aim of this study were designed, synthesised ten hybrids of flavones and its structure were characterised by various spectroscopic techniques such as FT-IR, GCMS and 1HNMR. Those compounds were subjected for insilico studies on multi-targeted diabetic enzymes such as Aldose reductase, protein tyrosine phosphatase and alpha amylase. Over all docking score afforded that alpha amylase were posses potential inhibition than the existed enzymes in the range of -7.18 to -9.81 Kcal/mol compared with their standard Acarbose (-7.61 Kcal/mol). Based on that, hybridised flavones were screened for invitro anti-diabetic activity by alpha amylase inhibitory assay. The invitro result was well correlated among the docking score and confirmed the anti-diabetic property of titled compounds. From which the compound HFa-HFc, with hydroxyl substitution on ring A showed noteworthy IC50 value compared with their standard Acarbose. This study summarised that the hybrids of flavones were pilot molecule for anti-diabetic activity.


Anti-diabetic Activity; Aldose reductase (AR); Protein Tyrosine Phosphatase 1B; alpha amylase; Docking Study.


Mealey BL, Ocampo GL. Diabetes mellitus and periodontal disease. Periodontology, 2007; 44(1): 127-153.

Helaine E, Resnick M. In This Issue of Diabetes Care. Diabetes Care, 2013; 36(6): 1431-1432.

Das S, Mitra I, Batuta S, Alam MN, Roy K, Begum NA. Design, synthesis and exploring the quantitative structure–activity relationship of some antioxidant flavonoid analogues. Bioorg. Med. Chem. Let, 2014; 24(21): 5050-5054.

Cushnie TP, Lamb AJ. Recent advances in understanding the antibacterial properties of flavonoids. Int. J. of Antimicrob. Agents, 2011; 38(2): 99-107.

Liu HB, Wang ZL, Qiao YX, Zhou JJ. Flavonoids with aldose reductase inhibiting activity: Pharmacophore modelling and implications for mechanism. Act. Phys. Chim. Sini, 2007; 23: 25-35.

Gonzalez R, Ballester I. Efects of flavonoids and other polyphenols on inflammation. Crit. Rev. Food. Sci. Nutr, 2011; 51(4): 331-362.

Nishiumi S, Miyamoto S. Dietary flavonoids as cancer preventive and therapeutic biofactors. Front. Biosci. (Schol Ed), 2011; 3: 1332-1362.

Unnikrishnan PS, Suthindhiran K, Jayasri MA. Alpha-amylase inhibition and antioxidant activity of marine green algae and its possible role in diabetes management. Pharmacogn Mag, 2015; 11: 511-515.

Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature, 2001; 414: 821-827.

Balaji RM, Jeyaram C, Sundaram KM, Ramasamy MS. Studies on Antidiabetic Activity of Indian Medicinal Plants Using α-Amylase and α-Glucosidase Inhibitory Activity-A Pathway to Antidiabetic Drugs. World. J. Med. Sci, 2015; 12: 207-212.

Mohan S, Nandhakumar L. Role of various flavonoids: Hypotheses on novel approach to treat diabetes. J. Med. Hypo. Id, 2014; 8: 1-6.

Garcia LA, Guillamon E, Villares A, Rostagno MA, Martinez JA. Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm Res, 2009; 58(9): 537-552.

Liu S, Li D, Huang B, Chen Y, Lu X, Wang Y. Inhibition of pancreatic lipase, α-glucosidase, α-amylase, and hypolipidemic effects of the total flavonoids from Nelumbo nucifera leaves. J. Ethnopharmacol, 2013; 149(1): 263-269.

Zhang S, Kumar K, Jiang X. DOVIS: an implementation for high through put virtual screening using Autodock. BMC Bioinform, 2008; 9: 126-128.

Cosconati S, Forli S, Perryman AL, Harris R, Goodsell DS, Olson AJ. Virtual screening with Autodock: Theory and Practice, Expert. Opin. Drug. Discov, 2010; 5(6): 597-607.

Wagner H, Farkas L, Synthesis of flavanoids, The flavanoids. Springer US, 1975;


Core AL, Hossain S, Cole AM, Phansteil O, Synthesis and bioevaluation of

substituted chalcones, coumaranones and other flavonoids as anti-HIV agents. Bioorg. Med. Chem. 2016; 24: 2768-2776.

Pramod S, Dasharath D, Ravi V, Pudukulatha, K, Cyclization of 2′- Hydroxyl chalcones to flavones using ammonium iodide as an iodine source – an eco- friendly approach. J. Serb. Chem. Soc. 2013; 78(7): 909 – 916.

Molecular Graphics Laboratory, The Scripps research Institute Available from:, graphics laboratory (MGL) tools and AutoDock4.2, downloaded on 25 July 2011.

Accelrys Available from:, Discovery studio visualizer 2.5.5 downloaded on 22 July 2011.

Advanced Chemistry Development Available from:, ChemSketch, ACD / Labs downloaded on 29 July 2011.

Shetty S, Secnik K, Oglesby A. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. Jl of Managed Care Pharm. 2005; 11: 559–564.

Miller GL. Use os dinitrosalicylic acid reagent for determination of reducing sugar, Anal.Chem.1959; 31(3): 426-428.

Ravindranath TM, Mong PY, Ananthakrishnan R, Li Q, Quadri N, Schmidt MA et al. Novel Role for Aldose Reductase in Mediating Acute Inflammatory Responses in the Lung. J. Immunol, 2009; 183: 8128-8137.

Hwang YC, Shaw S, Kaneko M. Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury. J. Fed. Am. Soci. Exp. Biol, 2005; 19: 795-797.

Hers HG. Le Mechanisme de la transformation de glucose en fructose par les vesicules seminales. Biochim. Biophys. Acta, 1956; 22: 202-203.

Van Heyningen R. Formation of polyols by the lens of the rat with sugar cataract. Nature, 1959; 468: 194-195.

Morrison AD, Clements RS, Travis SB, Oski F, Winegrad AI. Glucose utilization by the polyol pathway in human erythrocytes. Biochem. Biophys. Res. Commun, 1950; 40: 199-205.

Gonzalez RG, Barnett P, Aguayo J, Cheng HM, Chylack LTJ. Direct measurement of polyol pathway activity in the ocular lens. Diabetes, 1984; 33: 196-199.

Kinoshita JH, Nishimura C. The involvement of aldose Reductase in diabetic complications. Diab. Metab. Rev, 1998; 4: 323-337.

Pugliese G, Tilton GT, Williamson JR. Glucose induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diab. Metab. Rev, 1991; 7: 35-59.

Uma Maheswari M, Aji CS, Asokkumar K, Sivashanmugam T, Subhadradevi V, Jagannath P, Madeswaran A. In Silico Docking studies of Aldose Reductase Inhibitory activity of selected Flavonoids. Int. J. Drug Dev. & Res, 2012; 4(3): 328-334.

Pazhinskuy E, Ren J, Nair S. Pharmacological inhibition of protein tyrosine phosphate 1B: A promising strategy for the treatment of obesity and Type 2 diabetes mellitus. Curr. Med.Chem, 2013; 21: 2609-25.

Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatise 1B gene. Science, 1999; 283: 1544-48.

Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM et al. Increased energy expenditure, decreased adiposity and tissue specific insulin sensitivity in protein tyrosine phosphatase 1B deficient mice. Mol. Cell. Biol, 2000; 20(15): 5479-89.

Whitcomb DC, Lowe ME. Human Pancreatic Digestive Enzymes. Dig. Dis. Sci, 2007; 52: 1-17.

Van de Laar FA, Lucassen PLBJ, Akkermans RP, Van de Lisdonk EH, Rutten GEHM, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus, Cochrane Database of Systematic Reviews. 2005, Issue 2, Art. No: CD003639, DOI: 10.1002/14651858.CD003639.pub2.

Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA, 287(3), 2002, 360-372.

Goke B, Herrmann-Rinke C. The evolving role of alpha-glucosidase inhibitors. Diab. Metab. Rev, 14, 1998, S31-S38.

Lebowitz HE. Alpha-glucosidase inhibitors as agents in the treatment of diabetes. Diab. Rev, 1998; 6(2): 132-145.

Funke I, Melzing MF. Traditionally used plants in diabetes therapy - phytotherapeutics as inhibitors of a-amylase activity. Rev. Bras. Farmacogn., 2006; 16: 1-5.

Cheng AYY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes Mellitus. Can. Med. Assoc. J., 2005; 172: 213-226.




  • There are currently no refbacks.